22.74
+5.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tango Therapeutics
From its filings with the US Securities and Exchange Commission
Tango Therapeutics is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TNGX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $62.4m and a net loss of $101.6m. At that date it held total assets of $398.7m and shareholders' equity of $346.2m.
Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We leverage our state-of-the-art target and drug discovery platforms to identify novel disease-relevant targets and develop medicines tailored to defined patient populations with high unmet medical need. Our novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles, thus potentially maximizing clinical benefit.
We are currently focused on clinical development of two MTAP-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, our next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM).
In October 2025, we reported positive data from the ongoing Phase 1/2 clinical trial of vopimetostat monotherapy in patients with MTAP-deleted selective cancers, illustrating clinical activity across multiple cancer types with a favorable safety and tolerability profile. Specifically, the data in second-line MTAP-deleted pancreatic cancer demonstrated a median progression free survival (mPFS) of 7.2 months and 25% objective response rate (ORR), supporting the planned initiation of a 2L pivotal trial in this patient population in 2026.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Sept 2020
- Employees
- 137
- Website
- tangotx.com ↗
- Head office
- 201 BROOKLINE AVENUE, BOSTON, MA, 02215
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Alexis BorisyIndependent Chairman of the Board$318,401
- Dr. Barbara WeberPresident, Chief Executive Officer, Director, since 2017$6.5m
- Ms. Daniella BeckmanChief Financial Officer$3.2m
- Dr. Adam CrystalPresident - Research and Development$3.8m
- Mr. Douglas BarryChief Legal Officer, Chief Compliance Officer, Corporate Secretary$2.1m
- Ms. Lesley CalhounIndependent Director$300,651
- Mr. John KetchumIndependent Director$226,429
- Dr. Malte PetersIndependent Director$292,401
- Mr. Kanishka PothulaIndependent Director
- Dr. Mace RothenbergIndependent Director$296,151
- Mr. Elizabeth HickinVice President, IR and Corporate Communications, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 66
- Social
- 80
- Governance
- 43
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tango Therapeutics has 137 employees in Boston, US, focused on precision cancer medicine development.
- TNG908 is a methylthioadenosine cooperative inhibitor targeting PRMT5 in cancer cells with MTAP deletion.
- TNG462 is a more potent PRMT5 inhibitor with improved pharmacokinetic properties compared to TNG908.
Weaknesses
- Tango Therapeutics has 100 full-time employees as of the IPO listing date in 2020.
- The company's lead program TNG908 is still in clinical development stages.
- Tango Therapeutics has not yet commercialized any products as of the IPO listing date.
Opportunities
- Tango Therapeutics is developing TNG260 for checkpoint inhibitor resistance in STK11 mutant models.
- The company's TNG348 targets BRCA-mutant and HRD+ cancers with an allosteric USP1 inhibitor.
- Tango Therapeutics' clinical-stage focus offers potential for new cancer medicine approvals.
Threats
- Tango Therapeutics faces competition from other biotechnology firms in the Health Care sector.
- The company's clinical-stage development may encounter regulatory hurdles in the US market.
- Tango Therapeutics has not yet secured partnerships for product commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.